Factors associated with anti-tuberculosis medication adverse effects: A case-control study in Lima, Peru

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Chung Delgado, Kocfa ^a   Revilla Montag, Alejandro ^a   Guillen Bravo, Sonia ^a   Velez Segovia, Eduardo ^a   Soria Montoya, Andrea ^a   Nuñez Garbin, Alexandra ^a   Silva Caso, Wilmer ^a   Bernabe Ortiz, Antonio ^a  

^a UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ANEMIA; ANTIMICROBIAL THERAPY; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ABUSE; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDEPENDENT VARIABLE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OBESITY; PERU; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SMOKING; UNSPECIFIED SIDE EFFECT; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; TUBERCULOSIS;

NICOTIANA TABACUM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIABETES COMPLICATIONS; DRUG RESISTANCE, MULTIPLE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERU; SMOKING; TUBERCULOSIS; YOUNG ADULT;

EID: 81155137529     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027610     Document Type: Article

References (37)

1. World Health Organization (2010) Global Turberculosis Control 2010: Epidemiology Strategy Financing World Health Organization.
2. Ministerio de Salud (2006) Norma Técnica de Salud para el Control de la Tuberculosis. Ministerio de Salud. República de Perú.
3. Ministerio de Salud (2008) Informe de Gestión: Situación de la Tuberculosis en el Perú. Estrategia Sanitaria Nacional de Prevención y Control de la Tuberculosis. Ministerio de Salud. Lima, Perú.
4. USAID (2009) Tuberculosis profile: Peru USAID Press June pp. 1-2.
5. Bernabe-Ortiz A, (2007) La pobreza contraataca: Efectos sobre los resultados del TBC-DOTS en el Perú. Rev Med Hered 18: 179-180.
6. Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, et al. (2007) Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 11: 868-875.
7. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, et al. (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167: 1472-1477.
8. Xia YY, Zhan SY, (2007) [Systematic review of anti-tuberculosis drug induced adverse reactions in China]. Zhonghua Jie He He Hu Xi Za Zhi 30: 419-423.
9. World Health Organization (1968) Nutritional Anaemia. Report of a WHO scientific group. World Health Organization. Geneva, Switzerland.
10. World Health Organization (2011) Nutrition: Body mass index - BMI World Health Organization.
11. Ormerod LP, Horsfield N, (1996) Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 77: 37-42.
12. Forget EJ, Menzies D, (2006) Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 5: 231-249.
13. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, et al. (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23: 192-202.
14. Lee SW, Kang YA, Yoon YS, Um SW, Lee SM, et al. (2006) The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci 21: 1028-1032.
15. Rieder HL, (2002) Interventions for Tuberculosis Control and Elimination; International Union Against Tuberculosis and Lung Disease, editor. Paris, France.
16. Farga V, (2009) Resumen de Actividades del Comité Metropolitano de Tuberculosis: Selección de Temas 2008. Rev Chil Enferm Respir 25: 43-51.
17. Boldu J, Cebollero P, Abu J, De Prado A, (2007) [Treatment of pulmonary tuberculosis]. An Sist Sanit Navar 30 (Suppl 2): 99-115.
18. Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, et al. (2010) Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 132: 81-86.
19. Arbex MA, Varella Mde C, de Siqueira HR, de Mello FA, (2010) Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol 36: 626-640.
20. Geiseler PJ, Manis RD Jr, Maddux MS, (1985) Dosage of antituberculous drugs in obese patients. Am Rev Respir Dis 131: 944-946.
21. Reidenberg MM, (1977) Obesity and fasting-effects on drug metabolism and drug action in man. Clin Pharmacol Ther 22: 729-734.
22. Dye C, Bourdin Trunz B, Lonnroth K, Roglic G, Williams BG, (2011) Nutrition, diabetes and tuberculosis in the epidemiological transition. PLoS One 6: e21161.
23. Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S, (2009) Tuberculosis and nutrition. Lung India 26: 9-16.
24. Leung CC, Chang KC, (2008) Impact of lifestyle on tuberculosis. Respirology 13: 65-72.
25. Herrera S, Sanchez E, Lagunam A, Farroñay V, (2005) Tuberculosis multidrogoresistente en pacientes adultos mayores tratados en el Hospital Sergio E. Bernales Lima - Perú. Enferm Tórax 49: 181-185.
26. Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, et al. (2011) Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 133: 529-534.
27. Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, et al. (2005) Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9: 1373-1377.
28. Arbex MA, Varella Mde C, de Siqueira HR, de Mello FA, (2010) Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. J Bras Pneumol 36: 641-656.
29. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM, (2008) Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 177: 1391-1396.
30. Lee WM, (1995) Drug-induced hepatotoxicity. N Engl J Med 333: 1118-1127.
31. Yew WW, Leung CC, (2006) Antituberculosis drugs and hepatotoxicity. Respirology 11: 699-707.
32. Fernandez-Villar A, Sopena B, Vazquez R, Ulloa F, Fluiters E, et al. (2003) Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 36: 293-298.
33. Vilarica AS, Diogo N, Andre M, Pina J, (2010) Adverse reactions to antituberculosis drugs in in-hospital patients: Severity and risk factors. Rev Port Pneumol 16: 431-451.
34. Akolo C, Adetifa I, Shepperd S, Volmink J, (2010) Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev pp. CD000171.
35. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, et al. (2006) Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 61: 791-794.
36. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16: 75-83.
37. El Gharbi L, Baccar MA, Azzabi S, Aouina H, Kallel H, et al. (2006) [Risk factors of side effects of antituberculosis drugs]. Tunis Med 84: 487-491.